Neurotrophic factors-based therapeutic strategies in the spinal cord injury: an overview of recent preclinical studies in rodent models
Abstract Following the traumatic spinal cord injury (SCI) and initial mechanical insult, a cascade of secondary cellular and molecular events occurs at the trauma site. This phenomenon develops a toxic lesion environment with an inhibitory effect on axonal regeneration. The complicated pathophysiolo...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
Deznabi, Nazila [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Englisch |
| Erschienen: |
2023 |
|---|
| Schlagwörter: |
|---|
| Anmerkung: |
© The Author(s) 2023 |
|---|
| Übergeordnetes Werk: |
Enthalten in: The Egyptian journal of neurology, psychiatry and neurosurgery - Berlin : Springer, 2007, 59(2023), 1 vom: 10. Mai |
|---|---|
| Übergeordnetes Werk: |
volume:59 ; year:2023 ; number:1 ; day:10 ; month:05 |
| Links: |
|---|
| DOI / URN: |
10.1186/s41983-023-00661-3 |
|---|
| Katalog-ID: |
SPR051563002 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | SPR051563002 | ||
| 003 | DE-627 | ||
| 005 | 20230511064827.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230511s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1186/s41983-023-00661-3 |2 doi | |
| 035 | |a (DE-627)SPR051563002 | ||
| 035 | |a (SPR)s41983-023-00661-3-e | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Deznabi, Nazila |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Neurotrophic factors-based therapeutic strategies in the spinal cord injury: an overview of recent preclinical studies in rodent models |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a © The Author(s) 2023 | ||
| 520 | |a Abstract Following the traumatic spinal cord injury (SCI) and initial mechanical insult, a cascade of secondary cellular and molecular events occurs at the trauma site. This phenomenon develops a toxic lesion environment with an inhibitory effect on axonal regeneration. The complicated pathophysiology of SCI and limited central nervous system (CNS) to regeneration caused non-effective responses to drugs or beneficial treatments. Considering the necessity of SCI treatment as a critical issue in the medical field, finding novel therapeutic approaches and preclinical strategies to overcome secondary damage and functional recovery after SCI is the health system's priority. Different growth factors (GFs) are useful for treating SCI by promoting axonal regeneration and functional recovery. However, due to rapid degradation and dilution at the damaged site, direct administration of GFs is limited. In this regard, the type of delivered neurotrophic factors (NFs), administration mode, the time and location of application, and duration of treatment are critical factors in the therapy process. Also, in human studies adequate combination of NFs using cellular and viral vehicles with different tissue engineering materials is suggested to achieve satisfactory functional recovery following acute SCI. In this review, we summarize the finding of recent articles in the field of using different NFs and novel delivering systems for the treatment of SCI, which have been undertaken in rodent models. | ||
| 650 | 4 | |a Spinal cord injury |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Neurotrophic factors |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Functional recovery |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Brain-derived neurotrophic factor |7 (dpeaa)DE-He213 | |
| 700 | 1 | |a Hosseini, Samaneh |4 aut | |
| 700 | 1 | |a Rajabi, Mojgan |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t The Egyptian journal of neurology, psychiatry and neurosurgery |d Berlin : Springer, 2007 |g 59(2023), 1 vom: 10. Mai |w (DE-627)727814109 |w (DE-600)2686351-0 |x 1687-8329 |7 nnns |
| 773 | 1 | 8 | |g volume:59 |g year:2023 |g number:1 |g day:10 |g month:05 |
| 856 | 4 | 0 | |u https://dx.doi.org/10.1186/s41983-023-00661-3 |z kostenfrei |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_SPRINGER | ||
| 912 | |a GBV_ILN_20 | ||
| 912 | |a GBV_ILN_22 | ||
| 912 | |a GBV_ILN_23 | ||
| 912 | |a GBV_ILN_24 | ||
| 912 | |a GBV_ILN_31 | ||
| 912 | |a GBV_ILN_39 | ||
| 912 | |a GBV_ILN_40 | ||
| 912 | |a GBV_ILN_60 | ||
| 912 | |a GBV_ILN_62 | ||
| 912 | |a GBV_ILN_63 | ||
| 912 | |a GBV_ILN_65 | ||
| 912 | |a GBV_ILN_69 | ||
| 912 | |a GBV_ILN_73 | ||
| 912 | |a GBV_ILN_74 | ||
| 912 | |a GBV_ILN_95 | ||
| 912 | |a GBV_ILN_105 | ||
| 912 | |a GBV_ILN_110 | ||
| 912 | |a GBV_ILN_151 | ||
| 912 | |a GBV_ILN_161 | ||
| 912 | |a GBV_ILN_170 | ||
| 912 | |a GBV_ILN_206 | ||
| 912 | |a GBV_ILN_213 | ||
| 912 | |a GBV_ILN_230 | ||
| 912 | |a GBV_ILN_285 | ||
| 912 | |a GBV_ILN_293 | ||
| 912 | |a GBV_ILN_602 | ||
| 912 | |a GBV_ILN_2014 | ||
| 912 | |a GBV_ILN_4012 | ||
| 912 | |a GBV_ILN_4037 | ||
| 912 | |a GBV_ILN_4112 | ||
| 912 | |a GBV_ILN_4125 | ||
| 912 | |a GBV_ILN_4126 | ||
| 912 | |a GBV_ILN_4249 | ||
| 912 | |a GBV_ILN_4305 | ||
| 912 | |a GBV_ILN_4306 | ||
| 912 | |a GBV_ILN_4307 | ||
| 912 | |a GBV_ILN_4313 | ||
| 912 | |a GBV_ILN_4322 | ||
| 912 | |a GBV_ILN_4323 | ||
| 912 | |a GBV_ILN_4324 | ||
| 912 | |a GBV_ILN_4325 | ||
| 912 | |a GBV_ILN_4338 | ||
| 912 | |a GBV_ILN_4367 | ||
| 912 | |a GBV_ILN_4700 | ||
| 951 | |a AR | ||
| 952 | |d 59 |j 2023 |e 1 |b 10 |c 05 | ||
| author_variant |
n d nd s h sh m r mr |
|---|---|
| matchkey_str |
article:16878329:2023----::ertohcatrbsdhrpuisrtgeitepnlodnuynvriwfeetr |
| hierarchy_sort_str |
2023 |
| publishDate |
2023 |
| allfields |
10.1186/s41983-023-00661-3 doi (DE-627)SPR051563002 (SPR)s41983-023-00661-3-e DE-627 ger DE-627 rakwb eng Deznabi, Nazila verfasserin aut Neurotrophic factors-based therapeutic strategies in the spinal cord injury: an overview of recent preclinical studies in rodent models 2023 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © The Author(s) 2023 Abstract Following the traumatic spinal cord injury (SCI) and initial mechanical insult, a cascade of secondary cellular and molecular events occurs at the trauma site. This phenomenon develops a toxic lesion environment with an inhibitory effect on axonal regeneration. The complicated pathophysiology of SCI and limited central nervous system (CNS) to regeneration caused non-effective responses to drugs or beneficial treatments. Considering the necessity of SCI treatment as a critical issue in the medical field, finding novel therapeutic approaches and preclinical strategies to overcome secondary damage and functional recovery after SCI is the health system's priority. Different growth factors (GFs) are useful for treating SCI by promoting axonal regeneration and functional recovery. However, due to rapid degradation and dilution at the damaged site, direct administration of GFs is limited. In this regard, the type of delivered neurotrophic factors (NFs), administration mode, the time and location of application, and duration of treatment are critical factors in the therapy process. Also, in human studies adequate combination of NFs using cellular and viral vehicles with different tissue engineering materials is suggested to achieve satisfactory functional recovery following acute SCI. In this review, we summarize the finding of recent articles in the field of using different NFs and novel delivering systems for the treatment of SCI, which have been undertaken in rodent models. Spinal cord injury (dpeaa)DE-He213 Neurotrophic factors (dpeaa)DE-He213 Functional recovery (dpeaa)DE-He213 Brain-derived neurotrophic factor (dpeaa)DE-He213 Hosseini, Samaneh aut Rajabi, Mojgan aut Enthalten in The Egyptian journal of neurology, psychiatry and neurosurgery Berlin : Springer, 2007 59(2023), 1 vom: 10. Mai (DE-627)727814109 (DE-600)2686351-0 1687-8329 nnns volume:59 year:2023 number:1 day:10 month:05 https://dx.doi.org/10.1186/s41983-023-00661-3 kostenfrei Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 59 2023 1 10 05 |
| spelling |
10.1186/s41983-023-00661-3 doi (DE-627)SPR051563002 (SPR)s41983-023-00661-3-e DE-627 ger DE-627 rakwb eng Deznabi, Nazila verfasserin aut Neurotrophic factors-based therapeutic strategies in the spinal cord injury: an overview of recent preclinical studies in rodent models 2023 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © The Author(s) 2023 Abstract Following the traumatic spinal cord injury (SCI) and initial mechanical insult, a cascade of secondary cellular and molecular events occurs at the trauma site. This phenomenon develops a toxic lesion environment with an inhibitory effect on axonal regeneration. The complicated pathophysiology of SCI and limited central nervous system (CNS) to regeneration caused non-effective responses to drugs or beneficial treatments. Considering the necessity of SCI treatment as a critical issue in the medical field, finding novel therapeutic approaches and preclinical strategies to overcome secondary damage and functional recovery after SCI is the health system's priority. Different growth factors (GFs) are useful for treating SCI by promoting axonal regeneration and functional recovery. However, due to rapid degradation and dilution at the damaged site, direct administration of GFs is limited. In this regard, the type of delivered neurotrophic factors (NFs), administration mode, the time and location of application, and duration of treatment are critical factors in the therapy process. Also, in human studies adequate combination of NFs using cellular and viral vehicles with different tissue engineering materials is suggested to achieve satisfactory functional recovery following acute SCI. In this review, we summarize the finding of recent articles in the field of using different NFs and novel delivering systems for the treatment of SCI, which have been undertaken in rodent models. Spinal cord injury (dpeaa)DE-He213 Neurotrophic factors (dpeaa)DE-He213 Functional recovery (dpeaa)DE-He213 Brain-derived neurotrophic factor (dpeaa)DE-He213 Hosseini, Samaneh aut Rajabi, Mojgan aut Enthalten in The Egyptian journal of neurology, psychiatry and neurosurgery Berlin : Springer, 2007 59(2023), 1 vom: 10. Mai (DE-627)727814109 (DE-600)2686351-0 1687-8329 nnns volume:59 year:2023 number:1 day:10 month:05 https://dx.doi.org/10.1186/s41983-023-00661-3 kostenfrei Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 59 2023 1 10 05 |
| allfields_unstemmed |
10.1186/s41983-023-00661-3 doi (DE-627)SPR051563002 (SPR)s41983-023-00661-3-e DE-627 ger DE-627 rakwb eng Deznabi, Nazila verfasserin aut Neurotrophic factors-based therapeutic strategies in the spinal cord injury: an overview of recent preclinical studies in rodent models 2023 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © The Author(s) 2023 Abstract Following the traumatic spinal cord injury (SCI) and initial mechanical insult, a cascade of secondary cellular and molecular events occurs at the trauma site. This phenomenon develops a toxic lesion environment with an inhibitory effect on axonal regeneration. The complicated pathophysiology of SCI and limited central nervous system (CNS) to regeneration caused non-effective responses to drugs or beneficial treatments. Considering the necessity of SCI treatment as a critical issue in the medical field, finding novel therapeutic approaches and preclinical strategies to overcome secondary damage and functional recovery after SCI is the health system's priority. Different growth factors (GFs) are useful for treating SCI by promoting axonal regeneration and functional recovery. However, due to rapid degradation and dilution at the damaged site, direct administration of GFs is limited. In this regard, the type of delivered neurotrophic factors (NFs), administration mode, the time and location of application, and duration of treatment are critical factors in the therapy process. Also, in human studies adequate combination of NFs using cellular and viral vehicles with different tissue engineering materials is suggested to achieve satisfactory functional recovery following acute SCI. In this review, we summarize the finding of recent articles in the field of using different NFs and novel delivering systems for the treatment of SCI, which have been undertaken in rodent models. Spinal cord injury (dpeaa)DE-He213 Neurotrophic factors (dpeaa)DE-He213 Functional recovery (dpeaa)DE-He213 Brain-derived neurotrophic factor (dpeaa)DE-He213 Hosseini, Samaneh aut Rajabi, Mojgan aut Enthalten in The Egyptian journal of neurology, psychiatry and neurosurgery Berlin : Springer, 2007 59(2023), 1 vom: 10. Mai (DE-627)727814109 (DE-600)2686351-0 1687-8329 nnns volume:59 year:2023 number:1 day:10 month:05 https://dx.doi.org/10.1186/s41983-023-00661-3 kostenfrei Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 59 2023 1 10 05 |
| allfieldsGer |
10.1186/s41983-023-00661-3 doi (DE-627)SPR051563002 (SPR)s41983-023-00661-3-e DE-627 ger DE-627 rakwb eng Deznabi, Nazila verfasserin aut Neurotrophic factors-based therapeutic strategies in the spinal cord injury: an overview of recent preclinical studies in rodent models 2023 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © The Author(s) 2023 Abstract Following the traumatic spinal cord injury (SCI) and initial mechanical insult, a cascade of secondary cellular and molecular events occurs at the trauma site. This phenomenon develops a toxic lesion environment with an inhibitory effect on axonal regeneration. The complicated pathophysiology of SCI and limited central nervous system (CNS) to regeneration caused non-effective responses to drugs or beneficial treatments. Considering the necessity of SCI treatment as a critical issue in the medical field, finding novel therapeutic approaches and preclinical strategies to overcome secondary damage and functional recovery after SCI is the health system's priority. Different growth factors (GFs) are useful for treating SCI by promoting axonal regeneration and functional recovery. However, due to rapid degradation and dilution at the damaged site, direct administration of GFs is limited. In this regard, the type of delivered neurotrophic factors (NFs), administration mode, the time and location of application, and duration of treatment are critical factors in the therapy process. Also, in human studies adequate combination of NFs using cellular and viral vehicles with different tissue engineering materials is suggested to achieve satisfactory functional recovery following acute SCI. In this review, we summarize the finding of recent articles in the field of using different NFs and novel delivering systems for the treatment of SCI, which have been undertaken in rodent models. Spinal cord injury (dpeaa)DE-He213 Neurotrophic factors (dpeaa)DE-He213 Functional recovery (dpeaa)DE-He213 Brain-derived neurotrophic factor (dpeaa)DE-He213 Hosseini, Samaneh aut Rajabi, Mojgan aut Enthalten in The Egyptian journal of neurology, psychiatry and neurosurgery Berlin : Springer, 2007 59(2023), 1 vom: 10. Mai (DE-627)727814109 (DE-600)2686351-0 1687-8329 nnns volume:59 year:2023 number:1 day:10 month:05 https://dx.doi.org/10.1186/s41983-023-00661-3 kostenfrei Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 59 2023 1 10 05 |
| allfieldsSound |
10.1186/s41983-023-00661-3 doi (DE-627)SPR051563002 (SPR)s41983-023-00661-3-e DE-627 ger DE-627 rakwb eng Deznabi, Nazila verfasserin aut Neurotrophic factors-based therapeutic strategies in the spinal cord injury: an overview of recent preclinical studies in rodent models 2023 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © The Author(s) 2023 Abstract Following the traumatic spinal cord injury (SCI) and initial mechanical insult, a cascade of secondary cellular and molecular events occurs at the trauma site. This phenomenon develops a toxic lesion environment with an inhibitory effect on axonal regeneration. The complicated pathophysiology of SCI and limited central nervous system (CNS) to regeneration caused non-effective responses to drugs or beneficial treatments. Considering the necessity of SCI treatment as a critical issue in the medical field, finding novel therapeutic approaches and preclinical strategies to overcome secondary damage and functional recovery after SCI is the health system's priority. Different growth factors (GFs) are useful for treating SCI by promoting axonal regeneration and functional recovery. However, due to rapid degradation and dilution at the damaged site, direct administration of GFs is limited. In this regard, the type of delivered neurotrophic factors (NFs), administration mode, the time and location of application, and duration of treatment are critical factors in the therapy process. Also, in human studies adequate combination of NFs using cellular and viral vehicles with different tissue engineering materials is suggested to achieve satisfactory functional recovery following acute SCI. In this review, we summarize the finding of recent articles in the field of using different NFs and novel delivering systems for the treatment of SCI, which have been undertaken in rodent models. Spinal cord injury (dpeaa)DE-He213 Neurotrophic factors (dpeaa)DE-He213 Functional recovery (dpeaa)DE-He213 Brain-derived neurotrophic factor (dpeaa)DE-He213 Hosseini, Samaneh aut Rajabi, Mojgan aut Enthalten in The Egyptian journal of neurology, psychiatry and neurosurgery Berlin : Springer, 2007 59(2023), 1 vom: 10. Mai (DE-627)727814109 (DE-600)2686351-0 1687-8329 nnns volume:59 year:2023 number:1 day:10 month:05 https://dx.doi.org/10.1186/s41983-023-00661-3 kostenfrei Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 59 2023 1 10 05 |
| language |
English |
| source |
Enthalten in The Egyptian journal of neurology, psychiatry and neurosurgery 59(2023), 1 vom: 10. Mai volume:59 year:2023 number:1 day:10 month:05 |
| sourceStr |
Enthalten in The Egyptian journal of neurology, psychiatry and neurosurgery 59(2023), 1 vom: 10. Mai volume:59 year:2023 number:1 day:10 month:05 |
| format_phy_str_mv |
Article |
| institution |
findex.gbv.de |
| topic_facet |
Spinal cord injury Neurotrophic factors Functional recovery Brain-derived neurotrophic factor |
| isfreeaccess_bool |
true |
| container_title |
The Egyptian journal of neurology, psychiatry and neurosurgery |
| authorswithroles_txt_mv |
Deznabi, Nazila @@aut@@ Hosseini, Samaneh @@aut@@ Rajabi, Mojgan @@aut@@ |
| publishDateDaySort_date |
2023-05-10T00:00:00Z |
| hierarchy_top_id |
727814109 |
| id |
SPR051563002 |
| language_de |
englisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000naa a22002652 4500</leader><controlfield tag="001">SPR051563002</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230511064827.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230511s2023 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1186/s41983-023-00661-3</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)SPR051563002</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(SPR)s41983-023-00661-3-e</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Deznabi, Nazila</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Neurotrophic factors-based therapeutic strategies in the spinal cord injury: an overview of recent preclinical studies in rodent models</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2023</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">© The Author(s) 2023</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Abstract Following the traumatic spinal cord injury (SCI) and initial mechanical insult, a cascade of secondary cellular and molecular events occurs at the trauma site. This phenomenon develops a toxic lesion environment with an inhibitory effect on axonal regeneration. The complicated pathophysiology of SCI and limited central nervous system (CNS) to regeneration caused non-effective responses to drugs or beneficial treatments. Considering the necessity of SCI treatment as a critical issue in the medical field, finding novel therapeutic approaches and preclinical strategies to overcome secondary damage and functional recovery after SCI is the health system's priority. Different growth factors (GFs) are useful for treating SCI by promoting axonal regeneration and functional recovery. However, due to rapid degradation and dilution at the damaged site, direct administration of GFs is limited. In this regard, the type of delivered neurotrophic factors (NFs), administration mode, the time and location of application, and duration of treatment are critical factors in the therapy process. Also, in human studies adequate combination of NFs using cellular and viral vehicles with different tissue engineering materials is suggested to achieve satisfactory functional recovery following acute SCI. In this review, we summarize the finding of recent articles in the field of using different NFs and novel delivering systems for the treatment of SCI, which have been undertaken in rodent models.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Spinal cord injury</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Neurotrophic factors</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Functional recovery</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Brain-derived neurotrophic factor</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Hosseini, Samaneh</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Rajabi, Mojgan</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="t">The Egyptian journal of neurology, psychiatry and neurosurgery</subfield><subfield code="d">Berlin : Springer, 2007</subfield><subfield code="g">59(2023), 1 vom: 10. Mai</subfield><subfield code="w">(DE-627)727814109</subfield><subfield code="w">(DE-600)2686351-0</subfield><subfield code="x">1687-8329</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:59</subfield><subfield code="g">year:2023</subfield><subfield code="g">number:1</subfield><subfield code="g">day:10</subfield><subfield code="g">month:05</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://dx.doi.org/10.1186/s41983-023-00661-3</subfield><subfield code="z">kostenfrei</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_SPRINGER</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_31</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">59</subfield><subfield code="j">2023</subfield><subfield code="e">1</subfield><subfield code="b">10</subfield><subfield code="c">05</subfield></datafield></record></collection>
|
| author |
Deznabi, Nazila |
| spellingShingle |
Deznabi, Nazila misc Spinal cord injury misc Neurotrophic factors misc Functional recovery misc Brain-derived neurotrophic factor Neurotrophic factors-based therapeutic strategies in the spinal cord injury: an overview of recent preclinical studies in rodent models |
| authorStr |
Deznabi, Nazila |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)727814109 |
| format |
electronic Article |
| delete_txt_mv |
keep |
| author_role |
aut aut aut |
| collection |
springer |
| remote_str |
true |
| illustrated |
Not Illustrated |
| issn |
1687-8329 |
| topic_title |
Neurotrophic factors-based therapeutic strategies in the spinal cord injury: an overview of recent preclinical studies in rodent models Spinal cord injury (dpeaa)DE-He213 Neurotrophic factors (dpeaa)DE-He213 Functional recovery (dpeaa)DE-He213 Brain-derived neurotrophic factor (dpeaa)DE-He213 |
| topic |
misc Spinal cord injury misc Neurotrophic factors misc Functional recovery misc Brain-derived neurotrophic factor |
| topic_unstemmed |
misc Spinal cord injury misc Neurotrophic factors misc Functional recovery misc Brain-derived neurotrophic factor |
| topic_browse |
misc Spinal cord injury misc Neurotrophic factors misc Functional recovery misc Brain-derived neurotrophic factor |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
cr |
| hierarchy_parent_title |
The Egyptian journal of neurology, psychiatry and neurosurgery |
| hierarchy_parent_id |
727814109 |
| hierarchy_top_title |
The Egyptian journal of neurology, psychiatry and neurosurgery |
| isfreeaccess_txt |
true |
| familylinks_str_mv |
(DE-627)727814109 (DE-600)2686351-0 |
| title |
Neurotrophic factors-based therapeutic strategies in the spinal cord injury: an overview of recent preclinical studies in rodent models |
| ctrlnum |
(DE-627)SPR051563002 (SPR)s41983-023-00661-3-e |
| title_full |
Neurotrophic factors-based therapeutic strategies in the spinal cord injury: an overview of recent preclinical studies in rodent models |
| author_sort |
Deznabi, Nazila |
| journal |
The Egyptian journal of neurology, psychiatry and neurosurgery |
| journalStr |
The Egyptian journal of neurology, psychiatry and neurosurgery |
| lang_code |
eng |
| isOA_bool |
true |
| recordtype |
marc |
| publishDateSort |
2023 |
| contenttype_str_mv |
txt |
| author_browse |
Deznabi, Nazila Hosseini, Samaneh Rajabi, Mojgan |
| container_volume |
59 |
| format_se |
Elektronische Aufsätze |
| author-letter |
Deznabi, Nazila |
| doi_str_mv |
10.1186/s41983-023-00661-3 |
| title_sort |
neurotrophic factors-based therapeutic strategies in the spinal cord injury: an overview of recent preclinical studies in rodent models |
| title_auth |
Neurotrophic factors-based therapeutic strategies in the spinal cord injury: an overview of recent preclinical studies in rodent models |
| abstract |
Abstract Following the traumatic spinal cord injury (SCI) and initial mechanical insult, a cascade of secondary cellular and molecular events occurs at the trauma site. This phenomenon develops a toxic lesion environment with an inhibitory effect on axonal regeneration. The complicated pathophysiology of SCI and limited central nervous system (CNS) to regeneration caused non-effective responses to drugs or beneficial treatments. Considering the necessity of SCI treatment as a critical issue in the medical field, finding novel therapeutic approaches and preclinical strategies to overcome secondary damage and functional recovery after SCI is the health system's priority. Different growth factors (GFs) are useful for treating SCI by promoting axonal regeneration and functional recovery. However, due to rapid degradation and dilution at the damaged site, direct administration of GFs is limited. In this regard, the type of delivered neurotrophic factors (NFs), administration mode, the time and location of application, and duration of treatment are critical factors in the therapy process. Also, in human studies adequate combination of NFs using cellular and viral vehicles with different tissue engineering materials is suggested to achieve satisfactory functional recovery following acute SCI. In this review, we summarize the finding of recent articles in the field of using different NFs and novel delivering systems for the treatment of SCI, which have been undertaken in rodent models. © The Author(s) 2023 |
| abstractGer |
Abstract Following the traumatic spinal cord injury (SCI) and initial mechanical insult, a cascade of secondary cellular and molecular events occurs at the trauma site. This phenomenon develops a toxic lesion environment with an inhibitory effect on axonal regeneration. The complicated pathophysiology of SCI and limited central nervous system (CNS) to regeneration caused non-effective responses to drugs or beneficial treatments. Considering the necessity of SCI treatment as a critical issue in the medical field, finding novel therapeutic approaches and preclinical strategies to overcome secondary damage and functional recovery after SCI is the health system's priority. Different growth factors (GFs) are useful for treating SCI by promoting axonal regeneration and functional recovery. However, due to rapid degradation and dilution at the damaged site, direct administration of GFs is limited. In this regard, the type of delivered neurotrophic factors (NFs), administration mode, the time and location of application, and duration of treatment are critical factors in the therapy process. Also, in human studies adequate combination of NFs using cellular and viral vehicles with different tissue engineering materials is suggested to achieve satisfactory functional recovery following acute SCI. In this review, we summarize the finding of recent articles in the field of using different NFs and novel delivering systems for the treatment of SCI, which have been undertaken in rodent models. © The Author(s) 2023 |
| abstract_unstemmed |
Abstract Following the traumatic spinal cord injury (SCI) and initial mechanical insult, a cascade of secondary cellular and molecular events occurs at the trauma site. This phenomenon develops a toxic lesion environment with an inhibitory effect on axonal regeneration. The complicated pathophysiology of SCI and limited central nervous system (CNS) to regeneration caused non-effective responses to drugs or beneficial treatments. Considering the necessity of SCI treatment as a critical issue in the medical field, finding novel therapeutic approaches and preclinical strategies to overcome secondary damage and functional recovery after SCI is the health system's priority. Different growth factors (GFs) are useful for treating SCI by promoting axonal regeneration and functional recovery. However, due to rapid degradation and dilution at the damaged site, direct administration of GFs is limited. In this regard, the type of delivered neurotrophic factors (NFs), administration mode, the time and location of application, and duration of treatment are critical factors in the therapy process. Also, in human studies adequate combination of NFs using cellular and viral vehicles with different tissue engineering materials is suggested to achieve satisfactory functional recovery following acute SCI. In this review, we summarize the finding of recent articles in the field of using different NFs and novel delivering systems for the treatment of SCI, which have been undertaken in rodent models. © The Author(s) 2023 |
| collection_details |
GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 |
| container_issue |
1 |
| title_short |
Neurotrophic factors-based therapeutic strategies in the spinal cord injury: an overview of recent preclinical studies in rodent models |
| url |
https://dx.doi.org/10.1186/s41983-023-00661-3 |
| remote_bool |
true |
| author2 |
Hosseini, Samaneh Rajabi, Mojgan |
| author2Str |
Hosseini, Samaneh Rajabi, Mojgan |
| ppnlink |
727814109 |
| mediatype_str_mv |
c |
| isOA_txt |
true |
| hochschulschrift_bool |
false |
| doi_str |
10.1186/s41983-023-00661-3 |
| up_date |
2024-07-03T22:32:07.407Z |
| _version_ |
1803598878376722433 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000naa a22002652 4500</leader><controlfield tag="001">SPR051563002</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230511064827.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230511s2023 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1186/s41983-023-00661-3</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)SPR051563002</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(SPR)s41983-023-00661-3-e</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Deznabi, Nazila</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Neurotrophic factors-based therapeutic strategies in the spinal cord injury: an overview of recent preclinical studies in rodent models</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2023</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">© The Author(s) 2023</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Abstract Following the traumatic spinal cord injury (SCI) and initial mechanical insult, a cascade of secondary cellular and molecular events occurs at the trauma site. This phenomenon develops a toxic lesion environment with an inhibitory effect on axonal regeneration. The complicated pathophysiology of SCI and limited central nervous system (CNS) to regeneration caused non-effective responses to drugs or beneficial treatments. Considering the necessity of SCI treatment as a critical issue in the medical field, finding novel therapeutic approaches and preclinical strategies to overcome secondary damage and functional recovery after SCI is the health system's priority. Different growth factors (GFs) are useful for treating SCI by promoting axonal regeneration and functional recovery. However, due to rapid degradation and dilution at the damaged site, direct administration of GFs is limited. In this regard, the type of delivered neurotrophic factors (NFs), administration mode, the time and location of application, and duration of treatment are critical factors in the therapy process. Also, in human studies adequate combination of NFs using cellular and viral vehicles with different tissue engineering materials is suggested to achieve satisfactory functional recovery following acute SCI. In this review, we summarize the finding of recent articles in the field of using different NFs and novel delivering systems for the treatment of SCI, which have been undertaken in rodent models.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Spinal cord injury</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Neurotrophic factors</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Functional recovery</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Brain-derived neurotrophic factor</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Hosseini, Samaneh</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Rajabi, Mojgan</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="t">The Egyptian journal of neurology, psychiatry and neurosurgery</subfield><subfield code="d">Berlin : Springer, 2007</subfield><subfield code="g">59(2023), 1 vom: 10. Mai</subfield><subfield code="w">(DE-627)727814109</subfield><subfield code="w">(DE-600)2686351-0</subfield><subfield code="x">1687-8329</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:59</subfield><subfield code="g">year:2023</subfield><subfield code="g">number:1</subfield><subfield code="g">day:10</subfield><subfield code="g">month:05</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://dx.doi.org/10.1186/s41983-023-00661-3</subfield><subfield code="z">kostenfrei</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_SPRINGER</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_31</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">59</subfield><subfield code="j">2023</subfield><subfield code="e">1</subfield><subfield code="b">10</subfield><subfield code="c">05</subfield></datafield></record></collection>
|
| score |
7.4020357 |